X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.globenewswire.com/news-release/2024/05/08/2878179/0/en/Tarsus-Reports-First-Quarter-2024-Financial-Results-and-Recent-Business-Achievements.html
https://www.globenewswire.com//news-release/2024/03/05/2840447/0/en/Tarsus-Introduces-Mite-Party-Campaign-for-XDEMVY-lotilaner-ophthalmic-solution-0-25-to-Educate-Consumers-about-Demodex-Blepharitis.html
https://www.globenewswire.com//news-release/2024/02/22/2833632/0/en/Tarsus-Announces-Positive-Topline-Results-from-Carpo-a-Phase-2a-Proof-of-Concept-Tick-Kill-Trial-Evaluating-TP-05-lotilaner-for-the-Prevention-of-Lyme-Disease.html
https://www.globenewswire.com//news-release/2023/08/24/2731219/0/en/Now-Available-XDEMVY-lotilaner-ophthalmic-solution-0-25-the-First-and-Only-FDA-Approved-Treatment-for-Demodex-Blepharitis.html
https://www.fiercepharma.com/pharma/fda-clears-tarsus-xdemvy-first-treatment-target-common-eyelid-disease-caused-mites
https://www.fiercepharma.com/marketing/tarsus-launches-look-lids-campaign-painful-misdiagnosed-eyelid-condition
https://www.globenewswire.com/news-release/2022/09/07/2511308/0/en/Tarsus-Submits-New-Drug-Application-to-the-FDA-for-TP-03-for-the-Treatment-of-Demodex-Blepharitis.html
https://www.fiercebiotech.com/biotech/tarsus-takes-eyelid-mites-posts-positive-phase-3-data-it-preps-nda
Market Place
Share 
